Charles Hensley, Ph.D., and Itonis Pharmaceuticals Announce Anti-HIV Compound Targeting the Viral Entry Step
IRVINE, CA--(Marketwire - October 03, 2012) -
| Highlighted Links |
Itonis website |
Dr. Hensley commented, "Along with the preparation for the anti-nausea product we recently announced, we have been perfecting our anti-HIV technology. One attractive aspect of this technology is that it targets the viral entry step that gives it a broad application base. It is very important to protect this intellectual property before disseminating the specifics of the compound. We expect the process of protecting this valuable technology to begin over the coming weeks."
Itonis Pharmaceuticals recently announced that it will begin organizing clinical trials for its over-the-counter, systemically active anti-nausea preparation delivered via a nasal and/or sublingual spray for the alleviation of mild to moderate nausea. It also expects to begin organizing clinical trials for this new anti-HIV technology over the coming weeks.
About Itonis, Inc. and Itonis Pharmaceuticals
Itonis Pharmaceuticals is a new division of Itonis, Inc. that Itonis expects to convert into a new subsidiary. The division's mission is to create and market over-the-counter and prescription homeopathic products that better people's lives. These preparations will be categorized as derivative pharmaceuticals in that while the preparations will be both safe and effective, the path to market is faster than traditional pharmaceutical drugs. Dr. Charles Hensley is a pioneer in the development and marketing of safe and effective therapeutic nutraceutical and homeopathic preparations. He was a founder of Geltech, LLC that launched the Zicam® Cold Remedy, making the product a household name and forever changing the marketing and product placement paradigm for homeopathic drugs in the United States. Dr. Hensley and his team plan to use the same methodologies to revolutionize the treatment of several other common ailments and other chronic diseases.
For information on Itonis, Inc., please visit www.itonisholdings.com.
Safe Harbor:
Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's affiliates that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, seasonal changes, and other risks detailed from time to time in the Company's filings with the U.S. Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release.